Notably, the Hsp90 inhibitor pimitespib (Taiho Pharmaceutical Co. Ltd.)received approval in Japan in 2022 for the treatment of gastrointestinal stromal tumour (GIST) that has progressed after chemotherapy (Doi et al. 2024). This evidence concerns the gene HSP90AB1 and gastrointestinal stromal tumor.